GSK, iTeos Therapeutics' Phase 3 Lung Cancer Study: Market Implications Unfold

GlaxoSmithKline (GSK) and iTeos Therapeutics are conducting a Phase 3 clinical trial, GALAXIES Lung-301, to assess the safety and efficacy of belrestotug combined with dostarlimab versus pembrolizumab with placebo in high PD-L1 non-small-cell lung cancer patients. The trial aims to improve progression-free survival and overall survival compared to the current standard treatment. Positive results could positively impact GSK and iTeos Therapeutics' market performance, especially in the competitive oncology market.

GlaxoSmithKline (GSK) and iTeos Therapeutics are conducting a Phase 3 clinical trial, GALAXIES Lung-301, to assess the safety and efficacy of belrestotug combined with dostarlimab versus pembrolizumab with placebo in high PD-L1 non-small-cell lung cancer (NSCLC) patients. The trial aims to improve progression-free survival and overall survival compared to the current standard treatment.

The trial, which began on June 10, 2024, and was last updated on August 7, 2025, involves two main interventions: the experimental combination of biological agents dostarlimab and belrestotug, and the active comparator of pembrolizumab with a placebo. These treatments target the immune system to enhance cancer-fighting capabilities.

The study employs a randomized, double-blind design with quadruple masking to ensure unbiased results. The primary purpose of the trial is treatment-focused, aiming to provide new insights into NSCLC management.

Positive results from the trial could significantly impact GSK and iTeos Therapeutics' market performance, especially in the competitive oncology market. If the new combination shows substantial improvement over existing treatments, it could enhance investor confidence and potentially affect stock prices positively.

The study is ongoing, with further details available on the ClinicalTrials portal.

References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/GSK/pressreleases/34029255/gsk-and-iteos-therapeutics-promising-phase-3-lung-cancer-study-market-implications/